Exhibit 15.1
To the Board of Directors and Stockholders of
ABVC BioPharma, Inc
LETTER IN LIEU OF CONSENT FOR REVIEW REPORT
We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of ABVC BioPharma, Inc and its subsidiaries for the three-month periods ended March 31, 2024 and 2023, as the Company is initially filed on May 17, 2024; because we did not perform an audit, we expressed no opinion on that information.
We also are aware that the aforementioned report, pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act.
 | |
| San Mateo, California | WWC, P.C. |
| July 26, 2024 | Certified Public Accountants |
| PCAOB ID No. 1171 |
